ALVR News and Press, AlloVir Inc. From 11/02/23

2023-11-02 11:37:32 ET More on AlloVir AlloVir: An Intriguing $3 Biotech Concern AlloVir slips after multiple insider sales AlloVir spikes as Bank of America starts at Buy on lead asset Seeking Alpha’s Quant Rating on AlloVir Historical earning...

Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...

-- Posoleucel, a highly innovative off-the-shelf, multi-virus-specific investigational T cell therapy, continues to advance in three distinct, Phase 3, first-to-market indications in immunocompromised patients -- Enrollment in posoleucel pivotal Phase 3 multi-virus prevention, virus-assoc...

AlloVir Inc. (ALVR) is expected to report $-0.42 for Q3 2023

2023-09-21 14:44:37 ET Shares of AlloVir (NASDAQ: ALVR) fell as much as 7% early Thursday, then largely recovered to trade down around 0.7% as of 1:40 p.m. ET amid concerns over a lock-up agreement expiration for certain restricted stock units of the late clinical-stage cell therapy...

2023-09-18 13:13:33 ET For further details see: TTOO, ASTR and MBOT among mid-day movers

AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in the following upcoming investor conferences: Morgan Stanley 21 st Annual Global Healthcare Conference ...

2023-08-22 12:49:05 ET More on AlloVir AlloVir: 'Takes One To Know One' AlloVir: Several Late-Stage Programs Make This Worth A Look AlloVir spikes as Bank of America starts at Buy on lead asset AlloVir spikes as Gilead buys over $10M stock AlloVir gai...

2023-08-21 13:08:17 ET Gainers: Timber Pharmaceuticals ( TMBR ) +97% . China SXT Pharmaceuticals ( SXTC ) +92% . Novo Integrated Sciences ( NVOS ) +43% . Orchestra BioMed Holdings ( OBIO ) +27% . AlloVir ( ALVR ) +26% . The G...

AlloVir, Inc. (NASDAQ: ALVR) is one of today's top gainers. The company's shares are currently up 22.54% on the day to $3.48. Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies t...